Tower Research Capital LLC TRC Lowers Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Tower Research Capital LLC TRC cut its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 58.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,850 shares of the company's stock after selling 23,625 shares during the period. Tower Research Capital LLC TRC's holdings in Progyny were worth $291,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Signaturefd LLC increased its stake in shares of Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after acquiring an additional 1,355 shares in the last quarter. GAMMA Investing LLC grew its stake in Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after acquiring an additional 1,246 shares during the period. Nisa Investment Advisors LLC raised its holdings in Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after buying an additional 1,526 shares during the last quarter. Caitlin John LLC lifted its stake in shares of Progyny by 2,974.8% in the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after buying an additional 3,183 shares in the last quarter. Finally, Natixis bought a new stake in shares of Progyny during the fourth quarter worth about $69,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Down 0.2 %

Shares of Progyny stock traded down $0.04 during trading on Tuesday, reaching $23.36. The company's stock had a trading volume of 1,041,981 shares, compared to its average volume of 1,741,730. The company has a market cap of $2.00 billion, a price-to-earnings ratio of 40.28, a PEG ratio of 2.39 and a beta of 1.37. The firm's 50-day moving average is $21.90 and its two-hundred day moving average is $19.37. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $33.84.

Analyst Ratings Changes

A number of research firms have weighed in on PGNY. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a research note on Monday, March 31st. Bank of America raised their target price on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Canaccord Genuity Group increased their price target on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $23.64.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.